The antiparkinson efficacy of deprenyl derives from transient improvement that is likely to be symptomatic
Identifieur interne : 004D99 ( Main/Merge ); précédent : 004D98; suivant : 004E00The antiparkinson efficacy of deprenyl derives from transient improvement that is likely to be symptomatic
Auteurs : James W. Schulzer [Canada] ; E. Mak [Canada] ; D. B. Calne [Canada]Source :
- Annals of Neurology [ 0364-5134 ] ; 1992-12.
English descriptors
- KwdEn :
- MESH :
- chemical , therapeutic use : Selegiline.
- drug therapy : Parkinson Disease.
- physiopathology : Parkinson Disease.
- Humans, Models, Statistical, Survival Analysis.
Abstract
We undertook an analysis of the hazard functions derived from results published by the Parkinson Study Group following their investigation of deprenyl. Our findings indicate that the action of deprenyl is transient rather than sustained. We also infer that this effect may be mediated through alleviation of symptoms rather than by neuroprotection.
Url:
DOI: 10.1002/ana.410320614
Links toward previous steps (curation, corpus...)
- to stream Istex, to step Corpus: 000264
- to stream Istex, to step Curation: 000264
- to stream Istex, to step Checkpoint: 001D97
- to stream PubMed, to step Corpus: 001A43
- to stream PubMed, to step Curation: 001A43
- to stream PubMed, to step Checkpoint: 001A43
- to stream Ncbi, to step Merge: 000387
- to stream Ncbi, to step Curation: 000387
- to stream Ncbi, to step Checkpoint: 000387
Links to Exploration step
ISTEX:646021EC50AF72553A4CBD6D7A7FBA2FD56DBCF7Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">The antiparkinson efficacy of deprenyl derives from transient improvement that is likely to be symptomatic</title>
<author><name sortKey="Schulzer, James W" sort="Schulzer, James W" uniqKey="Schulzer J" first="James W." last="Schulzer">James W. Schulzer</name>
</author>
<author><name sortKey="Mak, E" sort="Mak, E" uniqKey="Mak E" first="E." last="Mak">E. Mak</name>
</author>
<author><name sortKey="Calne, D B" sort="Calne, D B" uniqKey="Calne D" first="D. B." last="Calne">D. B. Calne</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">ISTEX</idno>
<idno type="RBID">ISTEX:646021EC50AF72553A4CBD6D7A7FBA2FD56DBCF7</idno>
<date when="1992" year="1992">1992</date>
<idno type="doi">10.1002/ana.410320614</idno>
<idno type="url">https://api-v5.istex.fr/document/646021EC50AF72553A4CBD6D7A7FBA2FD56DBCF7/fulltext/pdf</idno>
<idno type="wicri:Area/Istex/Corpus">000264</idno>
<idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">000264</idno>
<idno type="wicri:Area/Istex/Curation">000264</idno>
<idno type="wicri:Area/Istex/Checkpoint">001D97</idno>
<idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Checkpoint">001D97</idno>
<idno type="wicri:doubleKey">0364-5134:1992:Schulzer J:the:antiparkinson:efficacy</idno>
<idno type="wicri:source">PubMed</idno>
<idno type="RBID">pubmed:1471871</idno>
<idno type="wicri:Area/PubMed/Corpus">001A43</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">001A43</idno>
<idno type="wicri:Area/PubMed/Curation">001A43</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">001A43</idno>
<idno type="wicri:Area/PubMed/Checkpoint">001A43</idno>
<idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">001A43</idno>
<idno type="wicri:Area/Ncbi/Merge">000387</idno>
<idno type="wicri:Area/Ncbi/Curation">000387</idno>
<idno type="wicri:Area/Ncbi/Checkpoint">000387</idno>
<idno type="wicri:doubleKey">0364-5134:1992:Schulzer M:the:antiparkinson:efficacy</idno>
<idno type="wicri:Area/Main/Merge">004D99</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">The antiparkinson efficacy of deprenyl derives from transient improvement that is likely to be symptomatic</title>
<author><name sortKey="Schulzer, James W" sort="Schulzer, James W" uniqKey="Schulzer J" first="James W." last="Schulzer">James W. Schulzer</name>
<affiliation wicri:level="1"><country xml:lang="fr">Canada</country>
<wicri:regionArea>Neurodegenerative Disorders Centre, Department of Medicine, University Hospital, Vancouver, BC</wicri:regionArea>
<wicri:noRegion>BC</wicri:noRegion>
</affiliation>
<affiliation wicri:level="1"><country>Canada</country>
<wicri:regionArea>Neurodegenerative Disorders Centre, Department of Medicine, University Hospital, 2211 Wesbrook Mall, Vancouver, BC</wicri:regionArea>
<wicri:noRegion>BC</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Mak, E" sort="Mak, E" uniqKey="Mak E" first="E." last="Mak">E. Mak</name>
<affiliation wicri:level="1"><country xml:lang="fr">Canada</country>
<wicri:regionArea>Neurodegenerative Disorders Centre, Department of Medicine, University Hospital, Vancouver, BC</wicri:regionArea>
<wicri:noRegion>BC</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Calne, D B" sort="Calne, D B" uniqKey="Calne D" first="D. B." last="Calne">D. B. Calne</name>
<affiliation wicri:level="1"><country xml:lang="fr">Canada</country>
<wicri:regionArea>Neurodegenerative Disorders Centre, Department of Medicine, University Hospital, Vancouver, BC</wicri:regionArea>
<wicri:noRegion>BC</wicri:noRegion>
</affiliation>
</author>
</analytic>
<monogr></monogr>
<series><title level="j">Annals of Neurology</title>
<title level="j" type="abbrev">Ann Neurol.</title>
<idno type="ISSN">0364-5134</idno>
<idno type="eISSN">1531-8249</idno>
<imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher>
<pubPlace>Hoboken</pubPlace>
<date type="published" when="1992-12">1992-12</date>
<biblScope unit="volume">32</biblScope>
<biblScope unit="issue">6</biblScope>
<biblScope unit="page" from="795">795</biblScope>
<biblScope unit="page" to="798">798</biblScope>
</imprint>
<idno type="ISSN">0364-5134</idno>
</series>
<idno type="istex">646021EC50AF72553A4CBD6D7A7FBA2FD56DBCF7</idno>
<idno type="DOI">10.1002/ana.410320614</idno>
<idno type="ArticleID">ANA410320614</idno>
</biblStruct>
</sourceDesc>
<seriesStmt><idno type="ISSN">0364-5134</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Humans</term>
<term>Models, Statistical</term>
<term>Parkinson Disease (drug therapy)</term>
<term>Parkinson Disease (physiopathology)</term>
<term>Selegiline (therapeutic use)</term>
<term>Survival Analysis</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Selegiline</term>
</keywords>
<keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Parkinson Disease</term>
</keywords>
<keywords scheme="MESH" qualifier="physiopathology" xml:lang="en"><term>Parkinson Disease</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Humans</term>
<term>Models, Statistical</term>
<term>Survival Analysis</term>
</keywords>
</textClass>
<langUsage><language ident="en">en</language>
</langUsage>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">We undertook an analysis of the hazard functions derived from results published by the Parkinson Study Group following their investigation of deprenyl. Our findings indicate that the action of deprenyl is transient rather than sustained. We also infer that this effect may be mediated through alleviation of symptoms rather than by neuroprotection.</div>
</front>
</TEI>
<double doi="10.1002/ana.410320614"><ISTEX><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">The antiparkinson efficacy of deprenyl derives from transient improvement that is likely to be symptomatic</title>
<author><name sortKey="Schulzer, James W" sort="Schulzer, James W" uniqKey="Schulzer J" first="James W." last="Schulzer">James W. Schulzer</name>
</author>
<author><name sortKey="Mak, E" sort="Mak, E" uniqKey="Mak E" first="E." last="Mak">E. Mak</name>
</author>
<author><name sortKey="Calne, D B" sort="Calne, D B" uniqKey="Calne D" first="D. B." last="Calne">D. B. Calne</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">ISTEX</idno>
<idno type="RBID">ISTEX:646021EC50AF72553A4CBD6D7A7FBA2FD56DBCF7</idno>
<date when="1992" year="1992">1992</date>
<idno type="doi">10.1002/ana.410320614</idno>
<idno type="url">https://api-v5.istex.fr/document/646021EC50AF72553A4CBD6D7A7FBA2FD56DBCF7/fulltext/pdf</idno>
<idno type="wicri:Area/Istex/Corpus">000264</idno>
<idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">000264</idno>
<idno type="wicri:Area/Istex/Curation">000264</idno>
<idno type="wicri:Area/Istex/Checkpoint">001D97</idno>
<idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Checkpoint">001D97</idno>
<idno type="wicri:doubleKey">0364-5134:1992:Schulzer J:the:antiparkinson:efficacy</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">The antiparkinson efficacy of deprenyl derives from transient improvement that is likely to be symptomatic</title>
<author><name sortKey="Schulzer, James W" sort="Schulzer, James W" uniqKey="Schulzer J" first="James W." last="Schulzer">James W. Schulzer</name>
<affiliation wicri:level="1"><country xml:lang="fr">Canada</country>
<wicri:regionArea>Neurodegenerative Disorders Centre, Department of Medicine, University Hospital, Vancouver, BC</wicri:regionArea>
<wicri:noRegion>BC</wicri:noRegion>
</affiliation>
<affiliation wicri:level="1"><country>Canada</country>
<wicri:regionArea>Neurodegenerative Disorders Centre, Department of Medicine, University Hospital, 2211 Wesbrook Mall, Vancouver, BC</wicri:regionArea>
<wicri:noRegion>BC</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Mak, E" sort="Mak, E" uniqKey="Mak E" first="E." last="Mak">E. Mak</name>
<affiliation wicri:level="1"><country xml:lang="fr">Canada</country>
<wicri:regionArea>Neurodegenerative Disorders Centre, Department of Medicine, University Hospital, Vancouver, BC</wicri:regionArea>
<wicri:noRegion>BC</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Calne, D B" sort="Calne, D B" uniqKey="Calne D" first="D. B." last="Calne">D. B. Calne</name>
<affiliation wicri:level="1"><country xml:lang="fr">Canada</country>
<wicri:regionArea>Neurodegenerative Disorders Centre, Department of Medicine, University Hospital, Vancouver, BC</wicri:regionArea>
<wicri:noRegion>BC</wicri:noRegion>
</affiliation>
</author>
</analytic>
<monogr></monogr>
<series><title level="j">Annals of Neurology</title>
<title level="j" type="abbrev">Ann Neurol.</title>
<idno type="ISSN">0364-5134</idno>
<idno type="eISSN">1531-8249</idno>
<imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher>
<pubPlace>Hoboken</pubPlace>
<date type="published" when="1992-12">1992-12</date>
<biblScope unit="volume">32</biblScope>
<biblScope unit="issue">6</biblScope>
<biblScope unit="page" from="795">795</biblScope>
<biblScope unit="page" to="798">798</biblScope>
</imprint>
<idno type="ISSN">0364-5134</idno>
</series>
<idno type="istex">646021EC50AF72553A4CBD6D7A7FBA2FD56DBCF7</idno>
<idno type="DOI">10.1002/ana.410320614</idno>
<idno type="ArticleID">ANA410320614</idno>
</biblStruct>
</sourceDesc>
<seriesStmt><idno type="ISSN">0364-5134</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass></textClass>
<langUsage><language ident="en">en</language>
</langUsage>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">We undertook an analysis of the hazard functions derived from results published by the Parkinson Study Group following their investigation of deprenyl. Our findings indicate that the action of deprenyl is transient rather than sustained. We also infer that this effect may be mediated through alleviation of symptoms rather than by neuroprotection.</div>
</front>
</TEI>
</ISTEX>
<PubMed><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">The antiparkinson efficacy of deprenyl derives from transient improvement that is likely to be symptomatic.</title>
<author><name sortKey="Schulzer, M" sort="Schulzer, M" uniqKey="Schulzer M" first="M" last="Schulzer">M. Schulzer</name>
<affiliation wicri:level="1"><nlm:affiliation>Department of Medicine, University Hospital, Vancouver, BC, Canada.</nlm:affiliation>
<country xml:lang="fr">Canada</country>
<wicri:regionArea>Department of Medicine, University Hospital, Vancouver, BC</wicri:regionArea>
<wicri:noRegion>BC</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Mak, E" sort="Mak, E" uniqKey="Mak E" first="E" last="Mak">E. Mak</name>
</author>
<author><name sortKey="Calne, D B" sort="Calne, D B" uniqKey="Calne D" first="D B" last="Calne">D B Calne</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="1992">1992</date>
<idno type="RBID">pubmed:1471871</idno>
<idno type="pmid">1471871</idno>
<idno type="doi">10.1002/ana.410320614</idno>
<idno type="wicri:Area/PubMed/Corpus">001A43</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">001A43</idno>
<idno type="wicri:Area/PubMed/Curation">001A43</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">001A43</idno>
<idno type="wicri:Area/PubMed/Checkpoint">001A43</idno>
<idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">001A43</idno>
<idno type="wicri:Area/Ncbi/Merge">000387</idno>
<idno type="wicri:Area/Ncbi/Curation">000387</idno>
<idno type="wicri:Area/Ncbi/Checkpoint">000387</idno>
<idno type="wicri:doubleKey">0364-5134:1992:Schulzer M:the:antiparkinson:efficacy</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">The antiparkinson efficacy of deprenyl derives from transient improvement that is likely to be symptomatic.</title>
<author><name sortKey="Schulzer, M" sort="Schulzer, M" uniqKey="Schulzer M" first="M" last="Schulzer">M. Schulzer</name>
<affiliation wicri:level="1"><nlm:affiliation>Department of Medicine, University Hospital, Vancouver, BC, Canada.</nlm:affiliation>
<country xml:lang="fr">Canada</country>
<wicri:regionArea>Department of Medicine, University Hospital, Vancouver, BC</wicri:regionArea>
<wicri:noRegion>BC</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Mak, E" sort="Mak, E" uniqKey="Mak E" first="E" last="Mak">E. Mak</name>
</author>
<author><name sortKey="Calne, D B" sort="Calne, D B" uniqKey="Calne D" first="D B" last="Calne">D B Calne</name>
</author>
</analytic>
<series><title level="j">Annals of neurology</title>
<idno type="ISSN">0364-5134</idno>
<imprint><date when="1992" type="published">1992</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Humans</term>
<term>Models, Statistical</term>
<term>Parkinson Disease (drug therapy)</term>
<term>Parkinson Disease (physiopathology)</term>
<term>Selegiline (therapeutic use)</term>
<term>Survival Analysis</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Selegiline</term>
</keywords>
<keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Parkinson Disease</term>
</keywords>
<keywords scheme="MESH" qualifier="physiopathology" xml:lang="en"><term>Parkinson Disease</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Humans</term>
<term>Models, Statistical</term>
<term>Survival Analysis</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">We undertook an analysis of the hazard functions derived from results published by the Parkinson Study Group following their investigation of deprenyl. Our findings indicate that the action of deprenyl is transient rather than sustained. We also infer that this effect may be mediated through alleviation of symptoms rather than by neuroprotection.</div>
</front>
</TEI>
</PubMed>
</double>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Canada/explor/ParkinsonCanadaV1/Data/Main/Merge
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 004D99 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Merge/biblio.hfd -nk 004D99 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= Wicri/Canada |area= ParkinsonCanadaV1 |flux= Main |étape= Merge |type= RBID |clé= ISTEX:646021EC50AF72553A4CBD6D7A7FBA2FD56DBCF7 |texte= The antiparkinson efficacy of deprenyl derives from transient improvement that is likely to be symptomatic }}
This area was generated with Dilib version V0.6.29. |